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Background:  Buprenorphine  is  an effective  treatment  for opioid  use disorder  but the  supply  of buprenor-
phine  physicians  is  currently  inadequate  to address  the  nation’s  prescription  opioid  crisis.  Perception  of
need due  to rising  opioid  overdose  rates  is one  possible  reason  for physicians  to  adopt  buprenorphine.
This  study  examined  associations  between  rates  of  growth  in  buprenorphine  physicians  and  prescription
opioid  overdose  mortality  rates  in  US  states.
Methods:  The  total  buprenorphine  physician  supply  and  number  of physicians  approved  to  treat  100
patients  (per  100,000  population)  were  measured  from  June  2013  to  January 2016.  States  were  divided
into  two groups:  those  with  rates  of  prescription  opioid  overdose  mortality  in 2013  at or  above  the
median  (>5.5  deaths  per 100,000  population)  and  those  with rates  below  the median.  State-level  growth
curves  were  estimated  using  mixed-effects  regression  to compare  rates  of growth  between  high and  low
overdose  states.
Results: The  total  supply  and  the  supply  of 100-patient  buprenorphine  physicians  grew significantly  (total
supply  from  7.7 to  9.9 per  100,000  population,  p <  0.001;  100-patient  supply  from  2.2 to  3.4 per  100,000
population,  p  < 0.001).  Rates  of growth  were  significantly  greater  in high  overdose  states  when  compared
to  low  overdose  states  (total  supply  b = 0.033,  p <  0.01;  100-patient  b =  0.022, p  < 0.01).
Conclusions:  The magnitude  of the  US  prescription  opioid  crisis,  as  measured  by  the  rate  of  prescription
opioid  overdose  mortality,  is  associated  with  growth  in the  number  of  buprenorphine  physicians.  Because
this  observational  design  cannot  establish  causality,  further  research  is  needed  to  elucidate  the  factors
influencing  physicians’  decisions  to begin  prescribing  buprenorphine.
© 2017  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The United States is now in the second decade of a prescrip-
tion opioid epidemic (Compton et al., 2015; Compton and Volkow,
2006) that has seen a rapid escalation of non-medical use (Han
et al., 2015) and prescription opioid use disorder rates that are
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jennifer.havens@uky.edu (J.R. Havens), michelle.lofwall@uky.edu (M.R. Lofwall),
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second only to marijuana in the most recent National Survey on
Drug Use and Health (Center for Behavioral Health Statistics and
Quality, 2015). Opioid use disorder has well-documented negative
consequences including premature mortality and family disrup-
tion, as well as acquisition and transmission of HIV and hepatitis
C (Mechanic, 2014; Paulozzi and Xi, 2008; Volkow et al., 2014).
Moreover, in recent years, many of those abusing prescription opi-
oids have transitioned to using heroin (Cerda et al., 2015; Jones,
2013), underscoring the potential negative outcomes associated
with abusing prescription opioids. Perhaps the most alarming trend
is that of prescription opioid-associated fatal overdoses. The cur-
http://dx.doi.org/10.1016/j.drugalcdep.2016.08.642
0376-8716/© 2017 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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rent opioid abuse epidemic has given rise to significantly greater
numbers of prescription-opioid associated fatal overdoses nation-
wide (Jones et al., 2013; Paulozzi et al., 2014; Rudd et al., 2016).
Concurrent with the dramatic rise in prescription opioid use dis-
order and subsequent fatal overdose rates has been the emergence
and expansion of buprenorphine as a treatment option. Buprenor-
phine is an effective treatment (Fiellin et al., 2008; Fudula et al.,
2003), although methadone may  be more effective than buprenor-
phine in retaining individuals in treatment (Mattick et al., 2014).
There has been a steady increase in buprenorphine’s diffusion, par-
ticularly in office-based practice (Altice et al., 2011; Dick et al.,
2015; Stein et al., 2015b). Buprenorphine is primarily delivered in
physicians’ offices, which is notable because of the historical segre-
gation of substance use disorder (SUD) treatment to organizations
outside of mainstream medicine (McLellan and Woodsworth, 2014;
Roman et al., 2011).
The regulatory system enacted under the US Drug Addiction
Treatment Act (DATA) of 2000 requires physicians who  intend to
prescribe Schedule III controlled substances to treat opioid depen-
dence to submit a notification of intent to the Substance Abuse
and Mental Health Services Administration (SAMSHA); currently,
buprenorphine is the only medication that is included under this
designation (Center for Substance Abuse Treatment, 2004). As of
spring 2016, physicians initially can only treat up to 30 patients
concurrently in their first year. In subsequent years, physicians can
expand their treatment capacity up to 100 patients at any given
time, but to do so, they must submit a second notification of intent.
Information about whether physicians can treat up to 30 patients at
any given time or up to 100 patients is maintained in the Controlled
Substances Act (CSA) Active Registrants database.
This aspect of buprenorphine’s regulation allows for measure-
ment of buprenorphine physician supply, which is a population-
adjusted measure of the number of physicians in a given geographic
area (Cooper, 2009). The current study defines total buprenor-
phine physician supply as the number of physicians who hold the
buprenorphine waiver per 100,000 residents within a state, and
we also measure the number of physicians who can treat up to
100 patients. Conceptually, growth in the total physician supply
is largely driven by physicians initially seeking the buprenorphine
waiver, and therefore, may  reflect physicians who  are responding
to the scope of the opioid epidemic. Submitting a notification to
treat up to 100 patients, because it can only occur after at least
one year of treating patients, suggests that physicians are directly
experiencing sufficient demand for treatment to warrant this larger
capacity.
Five recent studies have examined buprenorphine physician
supply, but none have measured the extent to which growth in sup-
ply is associated with the prescription opioid crisis within states.
Prior studies have examined the relationships between state poli-
cies and the supply of buprenorphine physicians within counties
(Stein et al., 2015a) as well as the rates of growth in buprenorphine
physician supply from 2002 to 2011 (Dick et al., 2015). Another
study of US counties found greater supplies in counties on the East
and West coasts and differences between rural and urban coun-
ties (Rosenblatt et al., 2015). A cross-sectional analysis of states
also reported significant regional variation as well as correlations
between buprenorphine physician supply and the availability of
other SUD treatment, the percentage of residents insured by Med-
icaid, and the rate of overdose mortality from heroin and other
opioids (Knudsen, 2015).
The present study builds upon our prior work, which exam-
ined buprenorphine physician supply over a 24-month period
and its associations with states’ implementation of the Affordable
Care Act (Knudsen et al., 2015). We  integrated information about
states’ decisions regarding the expansion of Medicaid and the build-
ing of state-based health insurance exchanges (Blumenthal and
Collins, 2014; Buttorff et al., 2015; Gluck, 2014). Compared to states
that both expanded Medicaid and established a state-based health
insurance exchange, growth in the total buprenorphine physician
supply was  significantly lower in states that had only adopted one
of these elements of ACA and lower in states that adopted nei-
ther of these elements. These differences in growth were confined
to 30-patient and total physician supply; there were not signifi-
cant differences in the supply of the more experienced 100-patient
physicians by ACA implementation.
This paper extends our work by considering two  additional
state characteristics while controlling for this ACA typology. The
magnitude of the prescription opioid crisis within states has not
been tested for its potential impact on the rates of growth in
buprenorphine physicians. Prior work has identified that the rate of
overdose mortality from heroin and prescription opioids combined
is positively correlated with the average number of 100-patient
physicians (Knudsen et al., 2015), but the association with prescrip-
tion opioid mortality alone has not been examined.
Conceptually, the extent of a state’s prescription opioid cri-
sis may  represent an important element of the outer context, or
environment, in which physicians’ decisions about pursuing the
buprenorphine waiver are made. Major theories of innovation
implementation suggest the outer context can affect decisions to
adopt and implement a novel intervention (Aarons et al., 2011;
Damschroder et al., 2009; Damschroder and Hagedorn, 2011;
Fixsen et al., 2005). As noted by Rogers (2003) in his classic work,
Diffusion of Innovations, innovations are more likely to spread when
there is a perceived need for change. Media attention and public
awareness regarding the prescription opioid crisis has increased
over time (Barry et al., 2016; McGinty et al., 2016), which may
increase the perceived need for solutions among physicians in
states with greater rates of overdose mortality. These implementa-
tion frameworks offer one rationale for why  the rates of growth in
buprenorphine physicians may  be greater in states with high rates
of prescription opioid overdose mortality.
Region of the country has been examined in cross-sectional
analyses of buprenorphine physician supply and controlled in
growth models for its relationship with the intercept (i.e., states’
baseline levels), but region has not been tested for its impact on
growth rates (Knudsen, 2015; Knudsen et al., 2015). Large mean
differences have been documented between the Northeast and the
South, Midwest, and West. From a public health perspective, it is
important to consider whether the Northeast is also advantaged in
its rate of growth in buprenorphine physicians because that would
widen the gap between the Northeast and other regions over time.
It is hypothesized that states with a more pronounced
prescription opioid problem, as measured by the rate of prescrip-
tion opioid-related overdose mortality, have experienced greater
growth in buprenorphine physician supply than states with a less
pronounced prescription opioid problem. We  also hypothesize that
states outside the Northeast will have significantly lower rates of
growth than Northeastern states. This study tests these hypotheses
by examining data on buprenorphine physician supply from June
2013 to January 2016.
2. Methods
2.1. Study design
Growth in the supply of buprenorphine physicians at the state-
level was measured using an observational design that integrated
data from several sources. The study team purchased a database to
extract information about buprenorphine physicians and collated
other state characteristics from publicly available data sources.
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2.2. Outcome variables
Two outcomes at the state-level were measured monthly using
information from the DEA’s CSA Active Registrants database: total
buprenorphine physician supply and 100-patient physician sup-
ply. For total buprenorphine physician supply, we  counted the
number of civilian physicians per 100,000 state residents in all
50 states and the District of Columbia that had been designated
with activity codes C1 and C4 (which indicate those physicians with
approved notifications of intent). We  used US Census data regard-
ing state population as the denominator (United States Census
Bureau, 2015b). A similar method was applied to measure the sup-
ply of physicians holding the 100-patient waivers.
2.3. Independent variables
The primary independent variable was a dichotomous indica-
tor of state-level prescription opioid overdose mortality in 2013.
State-level rates of prescription opioid overdose mortality were
extracted from the Centers for Disease Control and Prevention’s
WONDER Multiple Cause of Death database (2015) using a method-
ology similar to Bachhuber et al. (2014). This database is based on
death certificates of US residents, which are coded by states or CDC’s
National Center for Health Statistics and entered into the National
Vital Statistics System (Centers for Disease Control and Prevention,
2016). Our search parameters included intentional and uninten-
tional deaths (International Statistical Classification of Diseases,
10th revision [ICD-10], codes X40–X44, X60–X64, and Y10–Y14)
where prescription opioids were coded (T40.2–T40.4). Our search
parameters did not include deaths coded for heroin or opium (i.e.,
T40.0 and T40.1). We  then used a median split to create two  groups:
high overdose states (those with opioid overdose mortality at or
above 5.5 deaths per 100,000 residents in 2013; n = 26) and low
overdose states (defined as those with overdose mortality below 5.5
per 100,000 residents in 2013; n = 25). The coding of states is pre-
sented in Fig. 1. Generating an interaction term (month-by-group)
allowed for testing whether these two groups had differential rates
of growth in the two outcomes.
2.4. Other variables
To measure ACA implementation, we used the variable con-
structed for our prior study that combined information about states’
approaches to the Medicaid expansion and insurance exchanges
in May  2013 (Henry J. Kaiser Family Foundation, 2013a,b). ACA-
supportive states, the reference group, were those that expanded
Medicaid and established a state-based health insurance exchange
(n = 16, 31.4%). ACA-hybrid states implemented either the Medicaid
expansion or a state-based exchange, but not both (n = 11, 21.6%);
this group primarily consisted of states that expanded Medicaid.
States that declined the Medicaid expansion and did not set up a
state-based exchange were coded as ACA-resistant states (n = 24,
31.4%). An ACA typology-by-month interaction controlled for the
associations of ACA implementation with the growth rates.
Region was defined by the US Census Bureau (2015a) categories
of Northeast (reference; n = 9, 17.7% of states), Midwest (n = 12,
23.5%), South (n = 18, 35.3%), and West (n = 12, 23.5%). To test for
regional differences in growth, region was interacted with month,
and the Northeast served as the reference group.
Finally, we controlled three state characteristics that were sig-
nificantly associated with the baseline measures of buprenorphine
physicians supply in our previous work (Knudsen et al., 2015).
Insurance coverage was measured by the percentage of the state
population, averaged for 2012–2013, who were covered by Med-
icaid (Henry J. Kaiser Family Foundation, 2014); as we  previously
reported, the average state had 16.0% of its residents covered by
Medicaid (SD = 3.8). The number of OTPs offering methadone per
100,000 residents in mid-2013 was  calculated using SAMHSA’s
Treatment Locator (Substance Abuse and Mental Health Services
Administration, 2013), and averaged 0.4 OTPs per 100,000 res-
idents (SD = 0.3). The number of substance use disorder (SUD)
treatment facilities was also constructed using data from SAMHSA’s
Treatment Locator, which, as we  previously reported, averaged 4.7
programs per 100,000 residents (SD = 2.3).
2.5. Statistical analysis
As a preliminary test of growth, paired t-tests compared the June
2013 and January 2016 values of buprenorphine physician supply.
Mixed-effects regression was then used to estimate growth curve
models for the two  outcomes. This approach estimates within-
state change over time, such that each state has its own growth
curve. It tests for the associations of state-level characteristics on
the intercept (i.e., baseline of June 2013) and interactions for group
differences in growth (Rabe-Hesketh and Skronkal, 2012). We used
the “mixed” command in Stata 13.1 (StataCorp, 2013) with an
unstructured covariance matrix and maximum likelihood estima-
tion. Each outcome was estimated through a series of four models.
First, the model only included the time variable. Models 2 and
3 examined the associations between growth in buprenorphine
physicians with prescription opioid overdose mortality rates and
region, respectively. Finally, Model 4 included all study variables.
After estimating Model 4, the commands “margins” and “margin-
splot” were implemented to graph the growth rates by overdose
mortality and region, while adjusting for the other variables in the
final model (Mitchell, 2012).
3. Results
At baseline in June 2013, there were 22,572 buprenorphine
physicians in the US, and the average state-level total physician
supply was 7.7 buprenorphine physicians per 100,000 residents
(SD = 5.0). By January 2016, the number had rise to 28,711 physi-
cians, and the average total supply had increased to 9.9 (SD = 6.4),
which was  a statistically significant increase (t = −9.5, df = 50, p
< 0.001). Similarly, there was a significant increase in 100-patient
physicians from 2.2 (SD = 1.5) to 3.4 (SD = 2.3) physicians per
100,000 residents (t = −9.1, df = 50, p < 0.001). Nationally, the num-
ber of physicians holding the 100-patient waiver increased from
6316 to 9483 over the study period.
Four mixed-effects regression models of total buprenorphine
physician supply are presented in Table 1. Model 1 only included
a parameter for time. There was  a significant positive coefficient
for month, indicating significant growth in total buprenorphine
physician supply. Model 2 added the dichotomous variable for
high prescription opioid overdose states as well as its interaction
with time. This dichotomous variable, which represented the differ-
ence between high overdose and low overdose states in June 2013,
approached but did not achieve statistical significance (p=0.055,
two-tailed test). However, the interaction term was significant,
indicating that states in the higher prescription opioid overdose
mortality group experienced greater growth in total buprenorphine
physicians than states in the lower overdose group. The coefficient
for month in Model 2 was  somewhat smaller than Model 1 because
its meaning shifted with the inclusion of the interaction term; in
Model 2, the coefficient for month represented the average rate
of growth for states in the lower overdose group, a rate that still
differed significantly from zero as indicated by its p-value.
The third model in Table 1 focused on region and its interaction
with time. In Model 3, the coefficient for month represented the
average rate of growth in the referent category, meaning the rate
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Fig. 1. Map  of US states by high and low prescription opioid overdose mortality rates.
Notes. High overdose states (in gray) are those at or above 5.5 prescription opioid overdose deaths per 100,000 residents in 2013, based on data extracted from the CDC
(2015)  WONDER database. Low overdose states (in white) had fewer than 5.5 prescription opioid overdose deaths per 100,000 residents in 2013. The District of Columbia
was  in the group of low overdose states.
for Northeastern states. This positive rate of growth in Northeastern
states significantly differed from zero (p < 0.001). The three other
region-by-time interactions were statistically significant and neg-
ative in direction, indicating that compared to Northeastern states,
states in the South, Midwest, and West experienced slower rates of
growth in total buprenorphine physicians over the 32-month study
period. In addition, these three regions had significantly lower
numbers of buprenorphine physicians at the start of the study, as
indicated by the significant coefficients for these variables on the
intercept.
Model 4 presents the full model. The coefficient for month rep-
resented the average rate of growth when all of the interaction
terms were equal to zero, which translates to the group of states
that were in the Northeast and were ACA-supportive but had lower
prescription opioid mortality. The month coefficient was positive,
indicating an average rate of growth in such states that was  signif-
icantly greater than zero.
The full model supported both of our study hypotheses. Consis-
tent with Model 2 and our first hypothesis, states in the higher
prescription opioid mortality group had a significantly greater
rate of growth in total buprenorphine physicians, even after con-
trolling for ACA implementation and region. These differences in
growth, while adjusting for all other variables in the model, are
presented in Fig. 2a. Similarly, states in the South, Midwest, and
West had significantly lower rates of growth than Northeastern
states, which supported our second hypothesis (Fig. 2b). In addi-
tion, ACA-resistant states had a significantly lower rate of growth
when compared to ACA-supportive states in this final model. The
difference between ACA-hybrid and ACA-supportive states did not
achieve statistical significance (p = 0.065). Region was  negatively
correlated with the intercept, while the associations for Medi-
caid coverage, supply of OTPs, and supply of other SUD treatment
facilities were positive, indicating that these three variables were
associated with greater buprenorphine physician supply at the
starting point of the growth curve (i.e., June 2013).
Table 2 presents the results from applying the same model-
building strategy to the supply of 100-patient physicians. As seen
in Model 1, there was significant growth in the 100-patient physi-
cian supply over the 32-month study period. States with higher
prescription opioid overdose death rates experienced significantly
greater growth in the supply of 100-patient physicians, relative
to states with lower overdose death rates, and also had a greater
supply of 100-patient physicians at baseline (Model 2). Similar to
total physician supply, states in the South, Midwest, and West had
significantly lower rates of growth than Northeastern states, and
these states outside the Northeast also had significantly fewer 100-
patient physicians at the start of the observation period (Model
3).
In Model 4, which included all study variables, the differ-
ences identified in Models 2 and 3 for 100-patient buprenorphine
physician supply remained statistically significant, providing fur-
ther support for our two  hypotheses. States with higher rates
of prescription opioid mortality experienced significantly greater
growth in 100-patient physicians, even after controlling for the
other variables (Fig. 3a). The regional differences in growth rates
remained statistically significant (Fig. 3b). The ACA implementation
typology was  not associated with growth in the supply of physi-
cians approved to treat 100 patients. The associations between
the remaining state characteristics and the intercept for the 100-
patient buprenorphine physician supply were consistent with the
results from the model of total physician supply.
4. Discussion
This study extends prior research on the supply of physicians
able to prescribe buprenorphine by considering whether growth
at the state-level was  associated with the magnitude of the states’
prescription opioid overdose rates and region. Over a 32-month
observation period, states with higher rates of prescription opi-
oid overdose mortality (i.e., those with ≥5.5 deaths per 100,000
residents) experienced greater growth in total buprenorphine
physician supply and 100-patient physician supply than states with
lower rates of prescription opioid overdose mortality. Furthermore,
states in the South, Midwest, and West had significantly lower rates
of growth than states in the Northeast.
The greater growth of buprenorphine physicians in states with
higher rates of prescription opioid-related mortality could suggest
that physicians are responding to the magnitude of the prescrip-
tion opioid crisis. In a sense, overdose deaths represent the public
face of the prescription opioid crisis. Previous research has docu-
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Table  1
Growth curve model estimates of total buprenorphine physicians.
Model 1 Model 2 Model 3 Model 4
Unstandardized Coefficient
(95% CI)
Unstandardized Coefficient
(95% CI)
Unstandardized Coefficient
(95% CI)
Unstandardized Coefficient
(95% CI)
Month 0.072*** (0.057, 0.087) 0.052*** (0.032, 0.072) 0.131*** (0.102, 0.161) 0.131*** (0.100, 0.162)
Prescription overdose
mortality and region on the
growth rate
Month-by-high prescription
opioid overdose state
interaction
0.040** (0.012, 0.068) 0.033** (0.010, 0.055)
Month-by-Midwestern state
interaction
−0.097*** (−0.136, −0.058) −0.071*** (−0.108, −0.033)
Month-by-Southern state
interaction
−0.062** (−0.098, −0.026) −0.049** (−0.082, −0.015)
Month-by-Western state
interaction
−0.061** (−0.100, −0.022) −0.064*** (−0.098, −0.030)
Month-by-ACA-hybrid state
interaction
−0.031 (−0.644, 0.002)
Month-by-ACA-resistant state
interaction
−0.041** (−0.069, −0.013)
Time-invariant characteristics
on the intercept
High prescription opioid
overdose mortality (vs. low)
2.513 (−0.056, 5.082) 1.655** (0.406, 2.905)
Region
Northeast Reference Reference
Midwest −10.524*** (−13.440, −7.608) −5.349*** (−7.599, −3.099)
South  −8.188*** (−10.888, −5.488) −4.829*** (−6.787, −2.872)
West  −7.406*** (−10.322, −4.490) −4.222*** (−6.381, −2.064)
Typology of Affordable Care
Act implementation
ACA-supportive states Reference
ACA-hybrid states −1.039 (−2.813, 0.735)
ACA-resistant states −0.984 (−2.598, 0.630)
%  Medicaid-insured residents 0.356*** (0.203, 0.509)
Number of OTPs per 100,000
residents
5.964*** (3.151, 8.777)
Number of SUD treatment
facilities per 100,000 residents
0.288* (0.045, 0.531)
Intercept 7.540 (6.210, 8.870) 6.259 (4.424, 8.093) 14.649 (12.444, 16.853) 2.099 (−1.807, 6.004)
Random-Effects Parameters
State: Unstructured
Variance(Month) 0.003 (0.002, 0.004) 0.003 (0.002, 0.004) 0.002 (0.001, 0.003) 0.002 (0.001, 0.002)
Variance(Intercept) 23.476 (15.923, 34.610) 21.897 (14.852, 32.284) 11.381 (7.719, 16.780) 4.156 (2.778, 6.218)
Covariance(Month, Intercept) 0.208 (0.115, 0.300) 0.183 (0.100, 0.265) 0.102 (0.052, 0.152) 0.038 (0.012, 0.064)
Variance(Residual) .035 (.032, 0.037) 0.035 (0.032, 0.037) 0.035 (0.032, 0.037) 0.035 (0.032, 0.037)
Log  likelihood 58.669 62.349 77.814 101.873
Notes. CI = confidence interval. The interpretation of the month coefficient and intercept varies based on the variables included in the model. In Model 1, the month coefficient
represents the estimate for the average growth rate across all states, while the intercept represents the estimate for the average total buprenorphine physician supply at
the  start of the study. In subsequent models, the month coefficient represents the average growth rate for states in the lower prescription opioid overdose mortality group
(Model 2), for states in the Northeast (Model 3), and for Northeastern states that are ACA-supportive and in the low prescription opioid overdose mortality group (Model 4).
In  Models 2 and 3, the intercept represents the estimate for the average buprenorphine physician supply at the start of the study for the lower prescription mortality group
(Model  2) and for Northeastern states (Model 3); in Model 4, the intercept represents the average buprenorphine physician supply at the start of the study for Northeastern
states  that are ACA-supportive and in the low prescription opioid overdose mortality group if the other time-invariant state characteristics are set at zero. The Random Effects
Parameters provide estimates of the variability between states in their intercepts and slopes (i.e., growth curves).
* p < 0.05.
** p < 0.01.
*** p < 0.001 (two-tailed tests).
mented greater media coverage over time as rates of opioid-related
mortality have increased (Dasgupta et al., 2009; McGinty et al.,
2016). In such an environment, physicians may  perceive that there
will be sufficient patients to warrant obtaining a buprenorphine
waiver. However, the current study design could not directly test
this aspect of physician behavior. Although previous large-scale
surveys of buprenorphine physicians have documented some of the
professional characteristics of buprenorphine prescribers (Arfken
et al., 2010; Kissin et al., 2006; Netherland et al., 2009), there are
scant data on the motivations of physicians for submitting their
notification of intent to prescribe. Future studies should seek to
expand our understanding of why physicians, particularly those in
non-addiction specialties, adopt buprenorphine.
Regional differences, coupled with substantial differences at
baseline, point to disparities faced by residents in the South, Mid-
west and West. To consider whether these differences reflect states’
variability in treatment need, we  compared the rates of prescrip-
tion opioid overdose mortality by these four US Census regions and
found no significant differences. We  also compared state-specific
estimates of OUD in 2012, as reported by Jones et al. (2015), by
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Fig. 2. (a) Predictive Margins of Total Buprenorphine Physician Supply by Prescription Opioid Overdose Mortality. (b) Predictive Margins of Total Buprenorphine Physician
Supply  by Region.
Fig. 3. (a) Predictive Margins of 100-Patient Buprenorphine Physician Supply by Prescription Opioid Overdose Mortality. (b) Predictive Margins of 100-Patient Buprenorphine
Physician Supply by Region.
these four regions. Although Midwestern states had a lower rate
of OUD than Northeastern states, other pairwise regional compar-
isons were not significant (analyses available by request). Regional
differences in buprenorphine physician supply do not appear to
reflect major regional differences in the prevalence of OUD or the
prescription opioid overdose crisis. Future research should con-
tinue to explore the mechanisms that are driving these regional
differences. It is unknown whether regions vary in the amount of
public funding available for OUD treatment, cultural and political
norms about the causes and treatment of OUD, and the density of
medical training programs that include SUD treatment in the cur-
riculum. Testing whether these mechanisms account for some of
the regional differences in buprenorphine physician supply is an
important direction for future research.
These regional differences do suggest that efforts to sup-
port the diffusion of buprenorphine are still needed, particularly
in states outside the Northeast. The Physician Clinical Support
System-Buprenorphine (PCSS-B), now the Physician Clinical Sup-
port System for Medication-Assisted Treatment (http://pcssmat.
org), has been one important mechanism for providing sup-
port to physicians (Egan et al., 2010). Recent work to expand
buprenorphine in Massachusetts through technical assistance and
the employment of nurse care managers in community health cen-
ters has shown promise (LaBelle et al., 2016) and may be beneficial
in other states. Research on implementation strategies to increase
the likelihood that physicians begin prescribing buprenorphine
to opioid-dependent patients is still needed throughout the US
(Ducharme et al., 2016; Molfenter et al., 2015; Ober et al., 2015), but
our findings suggest the need for strategies to promote buprenor-
phine adoption is particularly acute outside the Northeast.
Continued growth in the supply of 100-patient physicians is
significant because such physicians are particularly important for
increasing access to treatment. Growth in 100-patient physicians
has been a critical driver in explaining the increases in the amount
of buprenorphine prescribed within US states (Stein et al., 2015b).
However, it is important to acknowledge that even with signifi-
cant growth in the number of buprenorphine physicians in the US,
there remains a gap between the capacity of the buprenorphine
treatment system and the number of Americans in need of OUD
treatment (Jones et al., 2015). In 2014, NSDUH data indicated that
1.9 million Americans had pain reliever use disorder and 500,000
had heroin use disorder (Center for Behavioral Health Statistics and
Quality, 2015). Our data from January 2016 indicated that 19,228
physicians could treat up to 30 patients and 9483 were approved
to treat up to 100 patients, yielding a treatment capacity of approx-
imately 1.5 million patients. Clearly, the supply of buprenorphine
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Table  2
Growth curve model estimates of physicians approved to treat up to 100 patients with buprenorphine.
Model 1 Model 2 Model 3 Model 4
Unstandardized Coefficient
(95% CI)
Unstandardized Coefficient
(95% CI)
Unstandardized Coefficient
(95% CI)
Unstandardized Coefficient
(95% CI)
Month 0.039*** (0.031, 0.047) 0.026*** (0.015, 0.037) 0.070*** (0.054, 0.086) 0.061*** (0.043, 0.078)
Prescription overdose
mortality and region on the
growth rate
Month-by-high prescription
opioid overdose state
interaction
0.025** (0.010, 0.040) 0.022** (0.009, 0.035)
Month-by-Midwestern state
interaction
−0.050*** (−0.071, −0.028) −0.041*** (−0.062, −0.020)
Month-by-Southern state
interaction
−0.027** (−0.047, −0.008) −0.026** (−0.045, −0.007)
Month-by-Western state
interaction
−0.041*** (−0.062, −0.020) −0.043*** (−0.062, −0.023)
Month-by-ACA-hybrid state
interaction
−0.001 (−0.020, 0.017)
Month-by-ACA-resistant state
interaction
−0.008 (−0.024, 0.008)
Time-invariant characteristics
on the intercept
High prescription opioid
overdose mortality (vs. low)
0.982* (0.225, 1.739) 0.747** (0.311, 1.182)
Region
Northeast Reference Reference
Midwest −3.194*** (−4.064, −2.325) −2.141*** (−2.914, −1.368)
South  −2.192*** (−2.996, −1.387) −1.542*** (−2.217, −0.866)
West  −2.655*** (−3.524, −1.786) −2.039*** (−2.776, −1.301)
Typology of Affordable Care
Act implementation
ACA-supportive states Reference
ACA-hybrid states 0.180 (−0.442, 0.802)
ACA-resistant states −0.106 (−0.664, 0.452)
%  Medicaid-insured residents 0.076** (0.028, 0.125)
Number of OTPs per 100,000
residents
1.200** (0.036, 2.093)
Number of SUD treatment
facilities per 100,000 residents
0.083* (0.006, 0.160)
Intercept 2.178 (1.776, 2.580) 1.677 (1.137, 2.218) 4.328 (3.671, 4.985) 1.283 (0.019, 2.548)
Random-Effects Parameters
State: Unstructured
Variance(Month) 0.0009 (0.0006, 0.0013) 0.0007 (0.0005, 0.0011) 0.0006 (0.0004, 0.0009) 0.0005 (0.0003, 0.0007)
Variance(Intercept) 2.143 (1.454, 3.160) 1.902 (1.290, 2.805) 1.010 (0.685, 1.490) 0.517 (0.345, 0.775)
Covariance(Month, Intercept) 0.035 (0.020, 0.051) 0.029 (0.016, 0.042) 0.018 (0.009, 0.026) 0.010 (0.004, 0.015)
Variance(Residual) 0.009 (0.008, 009) 0.009 (0.008, 0.009) 0.009 (0.008, 0.009) 0.009 (0.008, 0.009)
Log  likelihood 1220.816 1225.627 1241.030 1256.989
Notes. CI = confidence interval. The interpretation of the month coefficient and intercept varies based on the variables included in the model. In Model 1, the month coefficient
represents the estimate for the average growth rate across all states, while the intercept represents the estimate for the average 100-patient buprenorphine physician supply
at  the start of the study. In subsequent models, the month coefficient represents the average growth rate for states in the lower prescription opioid overdose mortality group
(Model  2), for states in the Northeast (Model 3), and for Northeastern states that are ACA-supportive and in the low prescription opioid overdose mortality group (Model 4).
In  Models 2 and 3, the intercept represents the estimate for the average buprenorphine physician supply at the start of the study for the lower prescription mortality group
(Model  2) and for Northeastern states (Model 3); in Model 4, the intercept represents the average buprenorphine physician supply at the start of the study for Northeastern
states  that are ACA-supportive and in the low prescription opioid overdose mortality group if the other time-invariant state characteristics are set at zero. The Random Effects
Parameters provide estimates of the variability between states in their intercepts and slopes (i.e., growth curves).
* p < 0.05.
** p < 0.01.
*** p < 0.001 (two-tailed tests).
physicians is not increasing at a pace fast enough to fully address
the size of the potential patient population in the US.
A recently released final rule, to be enacted in August 2016,
indicates that a new tier of patient limits will be added to the
US’s regulatory system for buprenorphine treatment (Department
of Health and Human Services, 2016). Physicians who have been
approved to treat 100 patients for at least a year will be able to sub-
mit  a third notification of intent to SAMHSA, which if approved, will
allow them to treat up to 275 concurrent patients. To be approved
for this higher limit, physicians are required to either meet stan-
dards of additional credentialing (e.g., board certification in an
addiction specialty or certification from the American Society of
Addiction Medicine, American Osteopathic Academy of Addiction
Medicine, or the American Board of Addiction Medicine) or to pro-
vide buprenorphine in a qualified practice setting. Such settings
must provide coverage for medical emergencies when practices are
closed, provide access to case management (directly or through
referral), use health information technology, be registered in the
prescription drug monitoring program in their state, and accept
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third-party payments. Physicians must re-apply every three years
to maintain their ability to treat up to 275 patients.
In describing the likely impact of this policy change, DHHS
(2016) included projections that this policy change would result
in approximately 40,000 additional patients receiving treatment in
the first year and that about 2000 physicians would likely apply
for the 275-patient limit over a five-year period. Given the num-
ber of Americans in need of treatment as indicated by Jones et al.
(2015), this increased capacity, while important, will still not fully
address the treatment gap. Future research is needed to monitor
the observed impacts of this policy change as well as the utility of
other strategies for increasing the nation’s capacity for delivering
medication-assisted treatment.
4.1. Limitations
This study has a number of limitations that warrant acknowl-
edgement. First, this research relies upon an observational
methodology that cannot firmly establish causality. Other unmea-
sured state characteristics may  be associated with the two
outcomes. Unmeasured efforts by key stakeholders, such as
SAMHSA, the American Society of Addiction Medicine (ASAM), the
American Academy of Addiction Psychiatry (AAAP), and others may
have prompted some physicians to obtain the waiver, and such
efforts cannot be controlled in the present study. Furthermore,
state-level data cannot explain the motivations of physicians who
have sought the buprenorphine waiver.
There are notable challenges when conducting analyses with
secondary data. For example, there are not monthly state-level
data available on prescription opioid overdose mortality, so this
variable cannot be measured with the same timing as our mea-
sure of buprenorphine physician supply. Although the measures
of prescription opioid overdose mortality from the CDC WONDER
database draw from the National Vital Statistics System, which is
the most comprehensive source of US mortality data, there are
known limitations to these data. As noted by Rudd et al. (2016),
state-level data on drug overdose mortality is subject to limita-
tions, such as variability in the toxicological testing performed at
autopsy and missing information about drug types on death certifi-
cates. In addition, we are unable to access data regarding physician
supply before June 2013; given that the prescription opioid epi-
demic began considerably earlier, this is another limitation of our
design.
Also, our findings are specific to buprenorphine, which is reg-
ulated very differently in the US than the methadone dispensing
system and the other SUD treatment medications (e.g., naltrexone)
that can be prescribed in physician offices. This unique regulatory
context, coupled with the distinct features of the US health care
system, means that our findings are unlikely to generalize to other
countries. In some countries, buprenorphine can be prescribed by
any physician (Auriacombe et al., 2004; Fatseas and Auriacombe,
2007; Strang et al., 2007) or by pharmacists (Nielsen et al., 2007),
which differs substantially from the US’s approach to this evidence-
based treatment.
Our measure of buprenorphine physician supply also has sub-
stantial limitations in measuring the availability of buprenorphine
treatment. Prior research has shown that many physicians hold the
waiver but do not actually prescribe this medication to patients
(Arfken et al., 2010), and this has been our experience in recruiting
a nationally representative sample of prescribers who have at least
one patient receiving buprenorphine for OUD.
5. Conclusions
The prescription opioid crisis in the United States is entrenched
and, thus far, has shown little evidence of abating. Greater access
to pharmacotherapy, such as buprenorphine, is greatly needed. The
current study found that the supply of buprenorphine physicians
has continued to grow, and that the rate of growth has been greater
in states that have experienced higher rates of prescription opioid
mortality. However, there are also substantial and persistent dif-
ferences in growth between the Northeast and other regions of the
country. Continued growth in the supply of buprenorphine physi-
cians is critically important as part of a larger national strategy to
address the prescription opioid epidemic.
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